AR080806A1 - Expresion del gen neurod1 en celulas epiteliales pancreaticas no endocrinas (nepec) - Google Patents

Expresion del gen neurod1 en celulas epiteliales pancreaticas no endocrinas (nepec)

Info

Publication number
AR080806A1
AR080806A1 ARP110100992A ARP110100992A AR080806A1 AR 080806 A1 AR080806 A1 AR 080806A1 AR P110100992 A ARP110100992 A AR P110100992A AR P110100992 A ARP110100992 A AR P110100992A AR 080806 A1 AR080806 A1 AR 080806A1
Authority
AR
Argentina
Prior art keywords
nepec
neurod1
human
insulin
cells
Prior art date
Application number
ARP110100992A
Other languages
English (en)
Inventor
Masayuki Shimoda
Shuyuan Chen
Hirofumi Noguchi
Shinichi Matsumoto
Paul A Grayburn
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR080806A1 publication Critical patent/AR080806A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1883Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Introduccion del gen NeuroD1 humano en células epiteliales pancreáticas no endocrinas (NEPEC) para producir células productoras de insulina in vitro. Se transfectaron NEPEC positivas citoqueratina (CK19) con plásmidos que codifican al gen NeuroD1 humano bajo un promotor CK19 humano. La caracterizacion posterior a la induccion permitio determinar que las NEPEC transfectadas c/plásmidos con NeuroD1 y promotor CK19 tres veces por día denominadas NEPEC+ND expresaban fuertemente NeuroD1 y ARNm de insulina. La relacion de células positivas para NeuroD1 a insulina humana en NEPEC+ND era significativamente mayor que en las NEPEC. Lo niveles de insulina y péptido C humanos en medios de cultivo en NEPEC+ND eran significativamente mayor que en NEPEC. Los hallazgos demuestran que el NeuroD1 humano bajo el control del promotor CK19 induce la diferenciacion de células NEPEC positivas para CK19 en células productoras de insulina. Reivindicacion 1: Un método de tratamiento de diabetes en un mamífero que lo necesita, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de un ácido nucleico aislado que incluye una secuencia que codifica un gen NeuroD1 en una o más células epiteliales pancreáticas no endocrinas de dicho mamífero y expresar una proteína NeuroD1 en la célula, en donde dicha proteína NeuroD1 comprende la secuencia de aminoácidos indicada en las SEQ ID N°: 10 o 12, para tratar así la diabetes del mamífero.
ARP110100992A 2010-03-24 2011-03-23 Expresion del gen neurod1 en celulas epiteliales pancreaticas no endocrinas (nepec) AR080806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31715910P 2010-03-24 2010-03-24

Publications (1)

Publication Number Publication Date
AR080806A1 true AR080806A1 (es) 2012-05-09

Family

ID=44673641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100992A AR080806A1 (es) 2010-03-24 2011-03-23 Expresion del gen neurod1 en celulas epiteliales pancreaticas no endocrinas (nepec)

Country Status (4)

Country Link
US (1) US20120009244A1 (es)
AR (1) AR080806A1 (es)
TW (1) TW201139675A (es)
WO (1) WO2011119890A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193330B2 (en) * 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
AU2002235728A1 (en) * 2001-02-26 2002-10-03 Novo Nordisk A/S Method for generating insulin-secreting cells suitable for transplantation
CN102282263B (zh) * 2008-11-13 2015-02-11 贝勒研究院 通过在体内递送的胰岛转录因子基因再生胰岛和逆转糖尿病

Also Published As

Publication number Publication date
US20120009244A1 (en) 2012-01-12
WO2011119890A1 (en) 2011-09-29
TW201139675A (en) 2011-11-16

Similar Documents

Publication Publication Date Title
AU2021204103B2 (en) Compositions and methods of preparing airway cells
Esteban et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells
Rony et al. Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming
Wang et al. Satellite cells, the engines of muscle repair
Cao et al. High glucose prevents osteogenic differentiation of mesenchymal stem cells via lncRNA AK028326/CXCL13 pathway
Li et al. Mesenchymal stem cells ameliorate LPS-induced acute lung injury through KGF promoting alveolar fluid clearance of alveolar type II cells
Chen et al. Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway
CA2876868A1 (en) Methods of preparing pluripotent stem cells
WO2014157257A1 (ja) 細胞の選別方法
Simmen et al. The Krüppel-like factors in female reproductive system pathologies
Wang et al. Differentiation of iPSCs into insulin-producing cells via adenoviral transfection of PDX-1, NeuroD1 and MafA
Bai et al. MicroRNAs can effectively induce formation of insulin‐producing cells from mesenchymal stem cells
CA2980852A1 (en) Means and methods for generation of breast stem cells
Wu et al. Smad7‑overexpressing rat BMSCs inhibit the fibrosis of hepatic stellate cells by regulating the TGF‑β1/Smad signaling pathway
Li et al. Neuronal restrictive silencing factor silencing induces human amniotic fluid-derived stem cells differentiation into insulin-producing cells
Saitoh et al. Tissue-specific stem cells obtained by reprogramming of non-obese diabetic (NOD) mouse-derived pancreatic cells confer insulin production in response to glucose
Yilmaz et al. Ectopic expression of Msx2 in mammalian myotubes recapitulates aspects of amphibian muscle dedifferentiation
US20210395692A1 (en) Method For Reducing Differentiation Resistance Of Pluripotent Stem Cells
AR080806A1 (es) Expresion del gen neurod1 en celulas epiteliales pancreaticas no endocrinas (nepec)
US20170175081A1 (en) Methods of Obtaining Islet Cells
Dave Extrinsic factors promoting insulin producing cell-differentiation and insulin expression enhancement-hope for diabetics.
Sun et al. Induction differentiation of rabbit adipose‑derived stromal cells into insulin‑producing cells in vitro
Peng et al. Involvement of gene methylation changes in the differentiation of human amniotic epithelial cells into islet-like cell clusters
Kaymak et al. Zrf1 controls mesoderm lineage genes and cardiomyocyte differentiation
US20240158788A1 (en) Methods and compositions used to modify chromatin architecture to regulate phenotype in aging and cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure